Altimmune Inc (ALT) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Altimmune Inc stock (ALT) is currently trading at $3.24. Altimmune Inc PS ratio (Price-to-Sales) is 10598.81. Analyst consensus price target for ALT is $18.00. WallStSmart rates ALT as Sell.
- ALT PE ratio analysis and historical PE chart
- ALT PS ratio (Price-to-Sales) history and trend
- ALT intrinsic value — DCF, Graham Number, EPV models
- ALT stock price prediction 2025 2026 2027 2028 2029 2030
- ALT fair value vs current price
- ALT insider transactions and insider buying
- Is ALT undervalued or overvalued?
- Altimmune Inc financial analysis — revenue, earnings, cash flow
- ALT Piotroski F-Score and Altman Z-Score
- ALT analyst price target and Smart Rating
Altimmune Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Altimmune Inc (ALT) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, revenue growth. Concerns around peg ratio and return on equity. Significant fundamental concerns warrant caution or avoidance.
Altimmune Inc (ALT) Key Strengths (2)
Revenue surging 420.00% year-over-year
Trading at 1.94x book value, attractively priced
Supporting Valuation Data
Altimmune Inc (ALT) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Very expensive relative to growth, significant premium
Very expensive at 10598.8x annual revenue
Small-cap company with higher risk but more growth potential
Moderate institutional interest at 42.55%
Supporting Valuation Data
Altimmune Inc (ALT) Detailed Analysis Report
Overall Assessment
This company scores 33/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 2 register as strengths (avg 9.0/10) while 6 fall into concern territory (avg 2.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Price/Book. Valuation metrics including Price/Book (1.94) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 420.00%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, PEG Ratio. Some valuation metrics including PEG Ratio (32.62), Price/Sales (10598.81) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -50.60%, Operating Margin at -111127.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -50.60% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 420.00% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ALT Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ALT's Price-to-Sales ratio of 10598.81x trades 1231% above its historical average of 796.03x (97th percentile), historically expensive. The current valuation is 59% below its historical high of 26048.15x set in Mar 2026, and 199126% above its historical low of 5.32x in Oct 2012. Over the past 12 months, the PS ratio has compressed from ~26048.2x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Altimmune Inc (ALT) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Altimmune Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 41,000 with 420% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Revenue growing at 420% YoY, reaching 41,000. This pace significantly outperforms most BIOTECHNOLOGY peers.
Spending 44900% of revenue (18M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -19M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Altimmune Inc maintain 420%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Altimmune Inc.
Bottom Line
Altimmune Inc is a high-conviction growth story with revenue accelerating at 420% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Altimmune Inc(ALT)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Altimmune, Inc., a clinical-stage biopharmaceutical company, focuses on the development of intranasal vaccines, immunomodulatory therapies, and treatments for liver disease. The company is headquartered in Gaithersburg, Maryland.